左右半大肠癌的差异

doi:10.3760/cma.j.issn.1673-422X.2015.04.018

摘要/Abstract

摘要： 结直肠癌的发病率在发达国家呈下降趋势，与结肠镜筛查、人口老龄化、饮食结构调整、癌症和糖尿病发病率升高等有关，性别、种族、教育等因素也起一定作用。右半大肠癌中，低分化和晚期疾病比例高，腺癌中黏液成分多，易出现并发症和肠内第二原发肿瘤；而左半大肠癌多呈高分化，诊断时偏早期。分子机制上，右半大肠癌与错配修复基因密切相关，而左半大肠癌与p53突变联系紧密。左、右半大肠癌存在众多表观和遗传学差异，可能属于两种不同的疾病，在临床工作和试验中应区别对待。

关键词: 结直肠肿瘤, 疾病特征, 肿瘤部位

Abstract: Decreasing trend has occurred in incidence of colorectal cancer in developed countries. A shift from left to right in location of colorectal cancer has been recognized, which may be associated with colonoscopy screening, aging population, diet structure modification, increased incidence of cancer and diabetes. Factors including sex, race and education may also play a role to some extent. Rightsided intestinal cancers have higher proportion of poor differentiation, terminal stage and mucinous component. Complications and second primary intestinal cancer are more common in rightsided intestinal cancers. Leftsided intestinal cancers tend to be well differentiated and at relatively early stage at diagnosis. With respect to molecular mechanism, rightsided cancers are associated with mismatch repair system, while leftsided cancers are related to p53 mutation. Based on the differences in clinicopathology and genetics, it′s implied that leftsided and rightsided intestinal cancers may belong to two different kind of disease. It′s suggested that attentions should be paid differently according to their respective characteristics in clinical practice and trials.

Key words: Colorectal neoplasms, Disease attributes, Neoplasm site

杨姣；傅健飞；钟献；袁瑛. 左右半大肠癌的差异[J]. 国际肿瘤学杂志, 2015, 42(4): 305-308.

Yang-Jiao-；Fu-Jian-Fei-；Zhong-Xian-；Yuan-Ying. Differences between right-sided and left-sided intestinal cancers[J]. Journal of International Oncology, 2015, 42(4): 305-308.

参考文献

［1］ Xu AG, Yu ZJ, Jiang B, et al. Colorectal cancer in Guangdong Province of China: A demographic and anatomic survey［J］. World J Gastroentero, 2010, 16(8): 960965. ［2］ Phipps AL, Scoggins J, Rossing MA, et al. Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 19752007［J］. Am J Public Health, 2012, 102(9): 17911797. ［3］ Meza R, Jeon J, Renehan AG, et al. Colorectal cancer incidence trends in the United States and United kingdom: evidence of right to leftsided biological gradients with implications for screening［J］. Cancer Res, 2010, 70(13): 54195429. ［4］ Brenner H, Hoffmeister M, Arndt V, et al. Protection from right and leftsided colorectal neoplasms after colonoscopy: populationbased study［J］. J Natl Cancer Inst, 2010, 102(2): 8995. ［5］ Benedix F, Schmidt U, Mroczkowski P, et al. Colon carcinoma—classification into right and left sided cancer or according to colonic subsite?—Analysis of 29,568 patients［J］. Eur J Surg Oncol, 2011, 37(2): 134139. ［6］ Collins BD. Risk of proximal colonic neoplasms in asymptomatic adults older than 50 years found to have distal hyperplastic polyps on routine colorectal cancer screening［J］. Perm J, 2010, 14(2): 1116. ［7］ Annema N, Heyworth JS, McNaughton SA, et al. Fruit and vegetable consumption and the risk of proximal colon, distal colon, and rectal cancers in a casecontrol study in Western Australia［J］. J Am Diet Assoc, 2011, 111(10): 14791490. ［8］ Leufkens AM, Van Duijnhoven FJ, Boshuizen HC, et al. Educational level and risk of colorectal cancer in EPIC with specific reference to tumor location［J］. Int J Cancer, 2012, 130(3): 622630. ［9］ Ghazi S, Lindforss U, Lindberg G, et al. Analysis of colorectal cancer morphology in relation to sex, age, location, and family history［J］. J Gastroenterol, 2012, 47(6): 619634. ［10］米登海,王燕慧. 阿司匹林与肿瘤防治［J］. 国际肿瘤学杂志, 2010, 37(6): 435437. ［11］ Rothwell PM, Wilson M, Elwin CE, et al. Longterm effect of aspirin on colorectal cancer incidence and mortality: 20year followup of five randomised trials［J］. Lancet, 2010, 376(9754): 17411750. ［12］ Brandstedt J, Wangefjord S, Nodin B, et al. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study［J］. Biol Sex Differ, 2012, 3(1): 23. ［13］ Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right and leftsided colon cancer: differences in epidemiology, perioperative course, histology, and survival［J］. Dis Colon Rectum, 2010, 53(1): 5764. ［14］ Kaku E, Oda Y, Murakami Y, et al. Proportion of flat and depressedtype and laterally spreading tumor among advanced colorectal neoplasia［J］. Clin Gastroenterol H, 2011, 9(6): 503508. ［15］ Hernandez MN, Sussman DA, Lee DJ, et al. Trends in colorectal cancer among hispanics by stage and subsite location: 19892006［J］. Clin Transl Gastroenterol, 2012, 3: e21. ［16］ Boisen MK, Johansen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer［J］. Ann Oncol, 2013, 24(10): 25542559. ［17］ Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage Ⅲ colon cancer from a randomized trial of FOLFOXbased adjuvant chemotherapy［J］. J Clin Oncol, 2013, 31(29): 36643672. ［18］ Cho YK, Kim HC, Kim SH, et al. Locationrelated differences in sporadic microsatellite unstable colorectal cancer［J］. Dig Liver Dis, 2010, 42(9): 611615. ［19］ Phipps AI, Lindor NM, Jenkins MA, et al. Colon and rectal cancer survival by tumor location and microsatellite instability: the Colon Cancer Family Registry［J］. Dis Colon Rectum, 2013, 56(8): 937944. ［20］ Zhao Y, Oki E, Ando K, et al. The impact of a highfrequency microsatellite instability phenotype on the tumor locationrelated genetic differences in colorectal cancer［J］. Cancer Genet Cytogenet, 2010, 196(2): 133139. ［21］ FariaSarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage Ⅱ and stage Ⅲ colon cancer patients［J］. Ann Oncol, 2010, 21(12): 23962402. ［22］ Pai RK, Jayachandran P, Koong AC, et al. BRAFmutated, microsatellitestable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features［J］. Am J Surg Pathol, 2012, 36(5): 744752. ［23］ Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis［J］. Dis Colon Rectum, 2012, 55(2): 128133. ［24］ Clancy C, Burke JP, Kalady MF, et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and metaanalysis［J］. Colorectal Dis, 2013, 15(12): e711e718. ［25］ Eklf V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer［J］. Br J Cancer, 2013, 108(10): 21532163. ［26］ Papagiorgis PC, Zizi AE, Tseleni S, et al. The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location［J］. Oncol Lett, 2012, 3(5): 11291135.

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[6]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[7]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[8]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[9]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[10]	陶红, 殷红, 罗宏, 陶佳瑜. 靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[11]	王熙, 吴川清. 结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[12]	高一钊, 刘洋, 刘秋龙, 邢金良. 循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[13]	何哲锋, 吴燚阳, 李振军, 应晓江. 炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.
[14]	赵莹, 张革红. AGR、PLR及NLR变化与转移性结直肠癌化疗疗效的相关性研究[J]. 国际肿瘤学杂志, 2022, 49(8): 473-477.
[15]	黄梦盼, 王学红, 芦永福. FOXA2在结直肠癌中的作用机制及其在诊疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(8): 490-493.